Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial

Fig. 1

Changes in markers of hematopoiesis, iron metabolism and inflammation. Mean absolute changes in (A) hemoglobin and (B) hematocrit over time. Mean percentage changes in (C) serum iron, (D) transferrin, (E) TSAT, (F) ferritin, (G) erythropoietin, (H) urinary MCP-1/Cr, (J) urinary IL-6/Cr and (K) serum IL-6. Numbers across bars represent between group differences in change relative to placebo group. Cr, creatinine; MCP-1, monocyte chemoattractant protein; IL-6, interleukin-6; TSAT, transferrin saturation

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840